Results 61 to 70 of about 3,981,458 (213)

Incidence of cancer chemotherapy-induced thrombocytopenia and its treatment outcomes at an oncology centre

Current Medicine Research and Practice
Background: Chemotherapy-induced thrombocytopenia (CIT) is a common haematological adverse effect in patients with cancer receiving cytotoxic chemotherapy.
K. Archana, J. Jaicey Cathorine, K. Bhuvaneswari   +2 more
doaj   +1 more source

A case series of necrotizing periodontal diseases in hospitalized patients: What hasn't been said yet?

Clinical Advances in Periodontics, EarlyView.
Abstract Background Necrotizing periodontal diseases (NPDs) are uncommon and severe inflammatory conditions characterized by tissue necrosis, painful ulceration, and rapid clinical progression, frequently associated with systemic immunosuppression. Limited data exist regarding their clinical presentation and management in hospital settings.
Osmaria Letthycia Carvalho Leal, Fernanda Bortolotto, Mariana Cristina Manoel, Gabriela Silveira de Araújo, Ana Carolina Fragoso Motta, Leandro Dorigan de Macedo, Lara Maria Alencar Ramos Innocentini, Joab Cabral Ramos, Isabel Schausltz Pereira Faustino   +8 more
wiley   +1 more source

Filgrastim induced thrombocytopenia.

, 2020
Drug-induced thrombocytopenia (DITP) is suggested by severe thrombocytopenia with subsequent recovery of platelet count after removal of the offending drug.
Haroun, Faysal, Kango, Ghazal
core   +1 more source

Clinical Outcomes of Gemcitabine Plus Nab‐Paclitaxel‐Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (NUPAT‐05): A Prospective, Single‐Arm, Phase II Study

International Journal of Cancer, EarlyView.
ABSTRACT Although chemoradiotherapy (CRT) has exhibited activity against locally advanced pancreatic cancer (LAPC), no standard regimen has been established. We previously completed a Phase I trial of CRT with gemcitabine plus nab‐paclitaxel (GnP) and established the recommended dose.
Hironori Yamada, Haruyoshi Tanaka, Suguru Yamada, Hideki Takami, Masamichi Hayashi, Nobuhiko Nakagawa, Keisuke Kurimoto, Yoshikuni Inokawa, Nobuyuki Watanabe, Takuya Ishikawa, Masayuki Okumura, Hiroshi Ogawa, Masahiko Ando, Osamu Maeda, Junpei Yamaguchi, Shinji Naganawa, Hiroki Kawashima, Tsutomu Fujii, Yukihiro Yokoyama, Tomoki Ebata, Mitsuro Kanda   +20 more
wiley   +1 more source

Thrombotic Microangiopathy Associated with Etoposide in Metastatic Lung Cancer: Diagnostic and Therapeutic Challenges

Journal of Oncological Sciences
Thrombotic microangiopathy (TMA) is a rare hematologic complication characterized by microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and variable involvement of organ systems.
Süleyman Sami GÜZEL, Zeliha Kübra ÇAKAN, Oğulcan KARALI, Hanne Beyza ÇAVLI, Nebi Serkan DEMİRCİ, Özkan ALAN   +5 more
doaj   +1 more source

Hypervision Proton Surgery: The Future Direction of Proton Therapy

iNew Medicine, EarlyView.
ABSTRACT Proton beams provide unique physical advantages characterized by a low entrance dose, negligible exit dose, and a sharp Bragg peak, which enable superior sparing of normal tissues and support safe dose escalation for improved tumor control. However, conventional photon‐based fractionation remains widely used in proton therapy, where prolonged ...
Li Li, Shuanghu Yuan
wiley   +1 more source

Bipolar Androgen Therapy as a Potential Mechanistic Bridge to Enhance PARP Inhibitor Efficacy in Prostate Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Prostate cancer remains a leading cause of cancer‐related mortality, largely driven by progression to metastatic castration‐resistant prostate cancer (mCRPC). Although poly(ADP‐ribose) polymerase inhibitors (PARPis) have improved outcomes in patients with homologous recombination repair (HRR) alterations, particularly in BRCA2‐mutated disease,
Jhen‐Hao Jhan, Jiun‐Hung Geng, Hung‐Lung Ke, Shu‐Pin Huang, Li Jia   +4 more
wiley   +1 more source

Overall Survival Benefit and Long‐Term Safety of Romiplostim in Persistent Chemotherapy‐Induced Thrombocytopenia

American Journal of Hematology, EarlyView.
Andrew B. Song, Gerald A. Soff
wiley   +1 more source

Long‐term outcomes of haploidentical hematopoietic stem cell transplantation with antithymocyte globulin–based myeloablative conditioning in pediatric refractory or relapsed non‐Hodgkin lymphoma

Pediatric Investigation, EarlyView.
Single‐center retrospective data showed that ATG‐based myeloablative haploidentical hematopoietic stem cell transplantation provides durable remission and favorable long‐term survival in children with refractory/relapsed non‐Hodgkin lymphoma, achieving high engraftment rates, low relapse incidence, and acceptable toxicity.
Chenguang Jia, Jie Zheng, Meng Yuan, Hongbo He, Yibo Fan, Bin Wang, Guanghua Zhu, Jun Yang, Yanhui Luo, Lixiao Cai, Pan Zhang, Yanlong Duan, Maoquan Qin   +12 more
wiley   +1 more source

Oral Azacitidine Maintenance After CPX‐351 in Transplant‐Ineligible Patients With Therapy‐Related or Myelodysplasia‐Related Acute Myeloid Leukemia

American Journal of Hematology, EarlyView.
Caroline Fileni, Edmond Chiche, David Swoboda, Alexander Coltoff, Rami Komrokji, Geoffrey Uy, Sarah Bertoli, Lenaig Le Clech, Mael Heiblig, Ludovic Gabellier, Patrick Lawrence, Lydia Kretschmer, Christoph Röllig, A. H. Wei, Fabio Guolo, Roberto Massimo Lemoli, Jeffrey Lancet, David Sallman, Thomas Cluzeau   +18 more
wiley   +1 more source